

We claim:

1. A method for treating an acute or chronic inflammatory disease which comprises administering to a patient in need thereof therapeutically effective amounts of a TNF binding protein and at least one additional anti-inflammatory drug, wherein said TNF binding protein and additional anti-inflammatory drug are administered separately or in combination.
2. The method of claim 1 wherein the anti-inflammatory drug is methotrexate (N-[4-[[2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid).
3. The method of claim 1 wherein the anti-inflammatory drug is a *fas* fusion protein.
4. The method of claim 1, wherein said TNF binding protein is wherein said TNF binding protein is sTNFR-I, sTNFR-II, sTNFR fragments or sTNFR Fc.
5. The method of any one of claims 1 through 4, wherein said inflammatory disease is an inflammatory disease of a joint.
6. The method of claim 5, wherein said inflammatory disease of a joint is rheumatoid arthritis.
7. The method of claim 3, wherein said TNF binding protein and said methotrexate are administered in a pharmaceutically acceptable carrier.
8. The method of claim 3, wherein said TNF binding protein and said *fas* fusion protein are administered in a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising a TNF binding protein and an additional anti-inflammatory drug.

5

10. The pharmaceutical composition wherein the anti-inflammatory drug is methotrexate.

11. The pharmaceutical composition wherein the anti-inflammatory drug is a *fas* fusion protein.

12. The pharmaceutical composition of claim 9, wherein said TNF binding protein is sTNFR-I, sTNFR-II, sTNFR fragments or sTNFR Fc.

15

13. The pharmaceutical composition of claim 9, wherein said TNF binding protein is present in an amount of up to about 20 mg.

20

14. The pharmaceutical composition of claim 10, wherein said methotrexate is present in an amount of up to about 25 mg.

15. A use of an anti-inflammatory drug, other than a non-TNF binding protein, in the preparation of a medicament for treating an acute or chronic inflammatory disease in a mammal in combination with the administration of a TNF binding protein.

30

16. The use of Claim 15, wherein the anti-inflammatory drug is methotrexate.

17. The use according to claim 16 wherein the methotrexate in the medicament is up to about 25 mg.

35

0907252 074701

18. The use according to claims 15 through 17 wherein said methotrexate is administered orally, intraperitoneally, subcutaneously or intravenously.

5 19. The use according to claims 15 through 17 wherein said methotrexate is administered orally.

20. The use of Claim 15, wherein the anti-inflammatory drug is a *fas* fusion protein.

10

21. A use of a TNF binding protein in the preparation of a medicament for treating an acute or chronic inflammatory disease in a mammal in combination with the administration of an additional
15 anti-inflammatory drug.

22. The use of according to Claim 21, wherein the anti-inflammatory drug is methotrexate.

20

23. The use according to claims 20 through 22 wherein said methotrexate is administered orally, intraperitoneally, subcutaneously or intravenously.

24. The use of according to Claim 21, wherein
25 the anti-inflammatory drug is a *fas* fusion protein.

25. The use according to claims 21 through 24 wherein the TNF binding protein is sTNFR-I, sTNFR-II, sTNFR fragments or sTNFR Fc.

30

26. The use according to Claims 21 through 25 wherein the TNF binding protein in the medicament is present in an amount of up to about 200 mg.

00907263 071701